These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 23301619)

  • 1. Identification of PDE6D as a molecular target of anecortave acetate via a methotrexate-anchored yeast three-hybrid screen.
    Shepard AR; Conrow RE; Pang IH; Jacobson N; Rezwan M; Rutschmann K; Auerbach D; Sriramaratnam R; Cornish VW
    ACS Chem Biol; 2013 Mar; 8(3):549-58. PubMed ID: 23301619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of the angiostatic cortisene anecortave acetate.
    Clark AF
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S26-34. PubMed ID: 17240253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation.
    Robin AL; Clark AF; Covert DW; Krueger S; Bergamini MV; Landry TA; Dickerson JE; Scheib SA; Realini T; Defaller JM; Cagle GD
    Am J Ophthalmol; 2009 Jan; 147(1):45-50.e2. PubMed ID: 18789793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypotensive effect of juxtascleral administration of anecortave acetate in different types of glaucoma.
    Prata TS; Tavares IM; Mello PA; Tamura C; Lima VC; Belfort R
    J Glaucoma; 2010 Sep; 19(7):488-92. PubMed ID: 20051887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit
    Kaya P; Schaffner-Reckinger E; Manoharan GB; Vukic V; Kiriazis A; Ledda M; Burgos Renedo M; Pavic K; Gaigneaux A; Glaab E; Abankwa DK
    J Med Chem; 2024 Jun; 67(11):8569-8584. PubMed ID: 38758695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical safety of anecortave acetate.
    Heaton J; Kastner P; Hackett R
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S35-40. PubMed ID: 17240255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and metabolism of anecortave acetate in animals and humans.
    Dahlin DC; Rahimy MH
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S49-61. PubMed ID: 17240257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate.
    Clark AF; Mellon J; Li XY; Ma D; Leher H; Apte R; Alizadeh H; Hegde S; McLenaghan A; Mayhew E; D'Orazio TJ; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1999 Aug; 40(9):2158-62. PubMed ID: 10440274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anecortave acetate.
    Bakri SJ; Kaiser PK
    Expert Opin Investig Drugs; 2006 Feb; 15(2):163-9. PubMed ID: 16433595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of human and mouse rod cGMP phosphodiesterase delta subunit (PDE6D) and chromosomal localization of the human gene.
    Li N; Florio SK; Pettenati MJ; Rao PN; Beavo JA; Baehr W
    Genomics; 1998 Apr; 49(1):76-82. PubMed ID: 9570951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization of the RAS:PDE6D Complex Is a Novel Strategy to Inhibit RAS Signaling.
    Yelland T; Garcia E; Parry C; Kowalczyk D; Wojnowska M; Gohlke A; Zalar M; Cameron K; Goodwin G; Yu Q; Zhu PC; ElMaghloob Y; Pugliese A; Archibald L; Jamieson A; Chen YX; McArthur D; Bower J; Ismail S
    J Med Chem; 2022 Feb; 65(3):1898-1914. PubMed ID: 35104933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes.
    Russell SR; Hudson HL; Jerdan JA;
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S79-90. PubMed ID: 17240260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216.
    Teng M; Lu W; Donovan KA; Sun J; Krupnick NM; Nowak RP; Li YD; Sperling AS; Zhang T; Ebert BL; Fischer ES; Gray NS
    J Med Chem; 2022 Jan; 65(1):747-756. PubMed ID: 34965125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical efficacy of anecortave acetate.
    Clark AF
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S41-8. PubMed ID: 17240256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prenyl-binding protein PrBP/δ: a chaperone participating in intracellular trafficking.
    Zhang H; Constantine R; Frederick JM; Baehr W
    Vision Res; 2012 Dec; 75():19-25. PubMed ID: 22960045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroid-induced iatrogenic glaucoma.
    Razeghinejad MR; Katz LJ
    Ophthalmic Res; 2012; 47(2):66-80. PubMed ID: 21757964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First clinical experience with anecortave acetate (Retaane).
    Hayek S; Scherrer M; Barthelmes D; Fleischhauer JC; Kurz-Levin MM; Menghini M; Helbig H; Sutter FK
    Klin Monbl Augenheilkd; 2007 Apr; 224(4):279-81. PubMed ID: 17458792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice.
    Jockovich ME; Murray TG; Escalona-Benz E; Hernandez E; Feuer W
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1264-8. PubMed ID: 16565356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anecortave (Alcon Laboratories).
    Vinores SA
    IDrugs; 2005 Apr; 8(4):327-34. PubMed ID: 15800808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabecular meshwork as a new target for the treatment of glaucoma.
    Ferrer E
    Drug News Perspect; 2006 Apr; 19(3):151-8. PubMed ID: 16804567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.